Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide

Regulatory Peptides

Volumn 109, Issue 1-3, 2002, Pages 199-208

  Voice, Julia K ^a   Dorsam, Glenn ^a   Chan, Robert C ^a   Grinninger, Carola ^a   Kong, Yvonne ^a   Goetzl, Edward J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allergy; Cytokines; G proteins; Hypersensitivity; Macrophages; Receptors; T cells

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; PROTEIN VPAC1RS; RECEPTOR PROTEIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALLERGIC DISEASE; ALLERGY; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CELL STIMULATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; HUMAN; IMMUNOREGULATION; MEMORY CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TRANSGENIC MOUSE;

ANIMALS; CELL DIFFERENTIATION; HUMANS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; T-LYMPHOCYTES; THYMUS GLAND; VASOACTIVE INTESTINAL PEPTIDE;

MUS MUSCULUS;

EID: 0037111638     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(02)00182-9     Document Type: Review

References (45)

1. Dorsam G., Voice J., Kong Y., Goetzl E.J. Vasoactive intestinal peptide mediation of development and functions of T lymphocytes. Ann. N.Y. Acad. Sci. 921:2000;79-91.
2. Said S.I., Mutt V. Vasointestinal peptide and related peptides. Ann. N.Y. Acad. Sci. 527:1988;1-691.
3. Goetzl E.J., Adelman D.C., Sreedharan S.P. Neuroimmunology. Adv. Immunol. 48:1990;161-190.
4. Gomariz R.P., Leceta J., Garrido E., Garrido T., Delgado M. Vasoactive intestinal peptide (VIP) mRNA expression in rat T and B lymphocytes. Regul. Pept. 50(2):1994;177-184.
5. Bellinger D.L., Lorton D., Brouxhon S., Felten S., Felten D.L. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv. Neuroimmunol. 6(1):1996;5-27.
6. Kaltreider H.B., Ichikawa S., Byrd P.K., Ingram D.A., Kishiyama J.L., Sreedharan S.P.et al. Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. Am. J. Respir. Cell Mol. Biol. 16(2):1997;133-144.
7. Ichikawa S., Sreedharan S.P., Owen R.L., Goetzl E.J. Immunochemical localization of type I VIP receptor and NK-1-type substance P receptor in rat lung. Am. J. Physiol. 268(4 Pt 1):1995;L584-L588.
8. Fink T., Weihe E. Multiple neuropeptides in nerves supplying mammalian lymph nodes: messenger candidates for sensory and autonomic neuroimmunomodulation? Neurosci. Lett. 90(1-2):1988;39-44.
9. Martinez C., Delgado M., Abad C., Gomariz R.P., Ganea D., Leceta J. Regulation of VIP production and secretion by murine lymphocytes. J. Neuroimmunol. 93(1-2):1999;126-138.
10. Delgado M., Ganea D. Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J. Immunol. 166(5):2001;2907-2912.
11. Delgado M., Abad C., Martinez C., Leceta J., Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 7(5):2001;563-568.
12. Xin Z., Jiang X., Wang H.Y., Denny T.N., Dittel B.N., Ganea D. Effect of vasoactive intestinal peptide (VIP) on cytokine production and expression of VIP receptors in thymocyte subsets. Regul. Pept. 72(1):1997;41-54.
13. Delgado M., Martinez C., Leceta J., Gomariz R.P. Vasoactive intestinal peptide in thymus: synthesis, receptors and biological actions. Neuroimmunomodulation. 6(1-2):1999;97-107.
14. Pankhaniya R., Jabrane Ferrat N., Gaufo G.O., Sreedharan S.P., Dazin P., Kaye J.et al. Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes. FASEB J. 12(1):1998;119-127.
15. Delgado M., Martinez C., Johnson M.C., Gomariz R.P., Ganea D. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J. Neuroimmunol. 68(1-2):1996;27-38.
16. Voice J.K., Dorsam G., Lee H., Kong Y., Goetzl E.J. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J. 15(13):2001;2489-2496.
17. Johnson M.C., McCormack R.J., Delgado M., Martinez C., Ganea D. Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA. J. Neuroimmunol. 68(1-2):1996;109-119.
18. Lara-Marquez M., O'Dorisio M., O'Dorisio T., Shah M., Karacay B. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J. Immunol. 166(4):2001;2522-2530.
19. Martinez C., Delgado M., Pozo D., Leceta J., Calvo J.R., Ganea D.et al. VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies. J. Neuroimmunol. 85(2):1998;155-167.
20. Delgado M., Munoz-Elias E.J., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J. Immunol. 162(3):1999;1707-1716.
21. Delgado M., Munoz-Elias E.J., Gomariz R.P., Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J. Neuroimmunol. 96(2):1999;167-181.
22. Martinez C., Delgado M., Pozo D., Leceta J., Calvo J.R., Ganea D.et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J. Leukoc. Biol. 63(5):1998;591-601.
23. Shimozato T., Kincade P.W. Indirect suppression of IL-7-responsive B cell precursors by vasoactive intestinal peptide. J. Immunol. 158(11):1997;5178-5184.
24. Delgado M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3. J. Immunol. 166(2):2001;1028-1040.
25. Johnston J.A., Taub D.D., Lloyd A.R., Conlon K., Oppenheim J.J., Kevlin D.J. Human T lymphocyte chemotaxis and adhesion induced by vasoactive intestinal peptide. J. Immunol. 153(4):1994;1762-1768.
26. Xia M., Leppert D., Hauser S.L., Sreedharan S.P., Nelson P.J., Krensky A.M.et al. Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane. J. Immunol. 156(1):1996;160-167.
27. Goetzl E.J., Sreedharan S.P. Mediators of communication and adaptation in the neuroendocrine and immune systems. FASEB J. 6(9):1992;2646-2652.
28. Ottaway C.A. In vitro alteration of receptors for vasoactive intestinal peptide changes the in vivo localization of mouse T cells. J. Exp. Med. 160(4):1984;1054-1069.
29. Xia M., Gaufo G.O., Wang Q., Sreedharan S.P., Goetzl E.J. Transduction of specific inhibition of HuT 78 human T cell chemotaxis by type I vasoactive intestinal peptide receptors. J. Immunol. 157(3):1996;1132-1138.
30. Sun L., Ganea D. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex. J. Neuroimmunol. 48(1):1993;59-69.
31. Wang H.Y., Xin Z., Tang H., Ganea D. Vasoactive intestinal peptide inhibits IL-4 production in murine T cells by a post-transcriptional mechanism. J. Immunol. 156(9):1996;3243-3253.
32. Martinez C., Delgado M., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. J. Immunol. 156(11):1996;4128-4136.
33. Mathew R.C., Cook G.A., Blum A.M., Metwali A., Felman R., Weinstock J.V. Vasoactive intestinal peptide stimulates T lymphocytes to release IL-5 in murine schistosomiasis mansoni infection. J. Immunol. 148(11):1992;3572-3577.
34. Jabrane-Ferrat N., Bloom D., Wu A., Li L., Lo D., Sreedharan S.P.et al. Enhancement by vasoactive intestinal peptide of gamma-interferon production by antigen-stimulated type 1 helper T cells. FASEB J. 13(2):1999;347-353.
35. Hassner A., Lau M.S., Goetzl E.J., Adelman D.C. Isotype-specific regulation of human lymphocyte production of immunoglobulins by sustained exposure to vasoactive intestinal peptide. J. Allergy Clin. Immunol. 92(6):1993;891-901.
36. Fujieda S., Waschek J.A., Zhang K., Saxon A. Vasoactive intestinal peptide induces S(alpha)/S(mu) switch circular DNA in human B cells. J. Clin. Invest. 98(7):1996;1527-1532.
37. Goetzl E.J., Voice J.K., Shen S., Dorsam G., Kong Y., West K.M.et al. Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc. Natl. Acad. Sci. U. S. A. 98(24):2001;13854-13859.
38. Xia M., Sreedharan S.P., Bolin D.R., Gaufo G.O., Goetzl E.J. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J. Pharmacol. Exp. Ther. 281(2):1997;629-633.
39. Goetzl E.J., Banda M.J., Leppert D. Matrix metalloproteinases in immunity. J. Immunol. 156(1):1996;1-4.
40. Xia M., Sreedharan S.P., Dazin P., Damsky C.H., Goetzl E.J. Integrin-dependent role of human T cell matrix metalloproteinase activity in chemotaxis through a model basement membrane. J. Cell. Biochem. 61(3):1996;452-458.
41. Delgado M., Munoz-Elias E.J., Kan Y., Gozes I., Fridkin M., Brenneman D.E.et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. J. Biol. Chem. 273(47):1998;31427-31436.
42. Dorsam G., Goetzl E.J. Vasoactive intestinal peptide receptor-1 (VPAC-1) Is a novel gene target of the hemolymphopoietic transcription factor Ikaros. J. Biol. Chem. 277(16):2002;13488-13493.
43. Paul S., Sun M., Mody R., Tewary H.K., Stemmer P., Massey R.J.et al. Peptidolytic monoclonal antibody elicited by a neuropeptide. J. Biol. Chem. 267:1992;13142-13145.
44. Li L., Sun M., Gao Q.S., Paul S. Low level formation of potent catalytic IgG fragments mediated by disulfide bond instability. Mol. Immunol. 33(7-8):1996;593-600.
45. Sun M., Gao Q.S., Kirnarskiy L., Rees A., Paul S. Cleavage specificity of a proteolytic antibody light chain and effects of the heavy chain variable domain. J. Mol. Biol. 271(3):1997;374-385.